1887
  1. Home
  2. Eurosurveillance
  3. Volume 27, Issue 30, 28/Jul/2022
  4. Article
Rapid communication Open Access
Like 0
Download

Abstract

This work evaluated neutralising antibody titres against wild type (WT) SARS-CoV-2 and four Omicron variants (BA.1, BA.2, BA.4 and BA.5) in healthcare workers who had breakthrough BA.1 infection. Omicron breakthrough infection in individuals vaccinated three or four times before infection resulted in increased neutralising antibodies against the WT virus. The fourth vaccine dose did not further improve the neutralising efficiency over the third dose against all Omicron variants, especially BA.4 and BA.5. An Omicron-specific vaccine may be indicated.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2022.27.30.2200559
2022-07-28
2024-12-22
/content/10.2807/1560-7917.ES.2022.27.30.2200559
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/27/30/eurosurv-27-30-2.html?itemId=/content/10.2807/1560-7917.ES.2022.27.30.2200559&mimeType=html&fmt=ahah

References

  1. Mor O, Mandelboim M, Fleishon S, Bucris E, Bar-Ilan D, Linial M, et al. The rise and fall of a local SARS-CoV-2 variant with the spike protein mutation L452R. Vaccines (Basel). 2021;9(8):937.  https://doi.org/10.3390/vaccines9080937  PMID: 34452062 
  2. Tegally H, Moir M, Everatt J, et al. Continued emergence and evolution of Omicron in South Africa: New BA.4 and BA.5 lineages. medRxiv2022 https://doi.org/10.1101/2022.05.01.22274406 
  3. Ou J, Lan W, Wu X, Zhao T, Duan B, Yang P, et al. Tracking SARS-CoV-2 Omicron diverse spike gene mutations identifies multiple inter-variant recombination events. Signal Transduct Target Ther. 2022;7(1):138.  https://doi.org/10.1038/s41392-022-00992-2  PMID: 35474215 
  4. Tegally H, Moir M, Everatt J, Giovanetti M, Scheepers C, Wilkinson E, et al. Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa. Nat Med. 2022.  https://doi.org/10.1038/s41591-022-01911-2  PMID: 35760080 
  5. Van Goethem N, Chung PYJ, Meurisse M, Vandromme M, De Mot L, Brondeel R, et al. Clinical severity of SARS-CoV-2 Omicron variant compared with Delta among hospitalized COVID-19 patients in Belgium during autumn and winter season 2021-2022. Viruses. 2022;14(6):1297.  https://doi.org/10.3390/v14061297  PMID: 35746768 
  6. Feikin DR, Abu-Raddad LJ, Andrews N, Davies MA, Higdon MM, Orenstein WA, et al. Assessing vaccine effectiveness against severe COVID-19 disease caused by omicron variant. Report from a meeting of the World Health Organization. Vaccine. 2022J;40(26):3516-27.  https://doi.org/10.1016/j.vaccine.2022.04.069  PMID: 35595662 
  7. Regev-Yochay G, Gonen T, Gilboa M, Mandelboim M, Indenbaum V, Amit S, et al. Efficacy of a fourth dose of Covid-19 mRNA vaccine against Omicron. N Engl J Med. 2022;386(14):1377-80.  https://doi.org/10.1056/NEJMc2202542  PMID: 35297591 
  8. Cao Y, Yisimayi A, Jian F, Song W, Xiao T, Wang L, et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature. 2022.  https://doi.org/10.1038/s41586-022-04980-y  PMID: 35714668 
  9. Yao L, Zhu K-L, Jiang X-L, Wang X-J, Zhan B-D, Gao H-X, et al. Omicron subvariants escape antibodies elicited by vaccination and BA.2.2 infection. Lancet Infect Dis. 2022;22(8):1116-7.  https://doi.org/10.1016/S1473-3099(22)00410-8  PMID: 35738299 
  10. Fan Y, Li X, Zhang L, Wan S, Zhang L, Zhou F. SARS-CoV-2 Omicron variant: recent progress and future perspectives. Signal Transduct Target Ther. 2022;7(1):141.  https://doi.org/10.1038/s41392-022-00997-x  PMID: 35484110 
COVID-19 vaccination and BA.1 breakthrough infection induce neutralising antibodies which are less efficient against BA.4 and BA.5 Omicron variants, Israel, March to June 2022
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Limor+Kliker&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Kliker Limor</a>, <a href="/search?value1=Neta+Zuckerman&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Zuckerman Neta</a>, <a href="/search?value1=Nofar+Atari&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Atari Nofar</a>, <a href="/search?value1=Noam+Barda&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Barda Noam</a>, <a href="/search?value1=Mayan+Gilboa&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Gilboa Mayan</a>, <a href="/search?value1=Ital+Nemet&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Nemet Ital</a>, <a href="/search?value1=Bayan+Abd+Elkader&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Abd Elkader Bayan</a>, <a href="/search?value1=Ilana+S+Fratty&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Fratty Ilana S</a>, <a href="/search?value1=Hanaa+Jaber&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Jaber Hanaa</a>, <a href="/search?value1=Ella+Mendelson&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Mendelson Ella</a>, <a href="/search?value1=Sharon+Alroy-Preis&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Alroy-Preis Sharon</a>, <a href="/search?value1=Yitshak+Kreiss&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Kreiss Yitshak</a>, <a href="/search?value1=Gili+Regev-Yochay&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Regev-Yochay Gili</a>, <a href="/search?value1=Michal+Mandelboim&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Mandelboim Michal</a></span>. COVID-19 vaccination and BA.1 breakthrough infection induce neutralising antibodies which are less efficient against BA.4 and BA.5 Omicron variants, Israel, March to June 2022 . <a href="/content/ecdc">Euro Surveill.</a> 2022;27(30):pii=2200559. <a href="https://doi.org/10.2807/1560-7917.ES.2022.27.30.2200559" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2022.27.30.2200559</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 12 Jul 2022;&nbsp;&nbsp; <span class="generated">Accepted</span>: 28 Jul 2022 </span> </p>
/content/10.2807/1560-7917.ES.2022.27.30.2200559
/content/10.2807/1560-7917.ES.2022.27.30.2200559
Loading

Data & Media loading...

Supplementary data

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error